Our data showed that short-term LBH589 administration effectively mitigated murine ARDS pathology, evidenced by reduced pulmonary edema, lung index, and suppressed the level of pro-inflammatory cytokines IL-1β/18 and IL-6 in lung tissue. Here, IL1B is linked to acute respiratory distress syndrome.